Scientists probe Brain's 'Early Warning' spot for Alzheimer's

NCT ID NCT06880510

Ongoing Knowledge-focused Sponsor: Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a small part of the brain called the locus coeruleus, which may be one of the first areas damaged in Alzheimer's disease. Researchers will use brain scans, eye tracking, and a mild nerve stimulation device to measure how this area affects attention and memory in 150 healthy adults. The goal is to better understand how the brain ages and find early clues to Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: transcutaneous auricular vagus nerve stimulator (taVNS)
What this could lead to: If successful, this could help identify early signs of Alzheimer's disease and point toward ways to preserve cognitive function.
What could go wrong: This is an early-stage observational study, not a treatment trial. It may not lead to direct benefits for participants, and results may not apply to all people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Cornell University

Ithaca, New York, 14850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.